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The senotherapeutic nicotinamide riboside raises platelet
nicotinamide adenine dinucleotide levels but cannot prevent
storage lesion
Willem Delabie,1 Wim Maes,2 Rosalie Devloo,1 Michelle R. Van den Hauwe,1 Karen Vanhoorelbeke,2
Veerle Compernolle,1,3,4 and Hendrik B. Feys 1,3,4
BACKGROUND: Supplementation of the nicotinamide
adenine dinucleotide (NAD) precursor nicotinamide
riboside (NR) has recently been shown to increase life-
span of cells, tissues, and entire organisms.
[Correction added on 13 December 2019, after first
online publication: In the preceding sentence, “adenine
nicotinamide” was revised to “nicotinamide adenine.”]
The impact of NR on platelet longevity has not been
tested.
STUDY DESIGN AND METHODS: A pool-and-split
design of buffy coat derived platelet concentrates (PCs)
was used. One arm was treated with cumulative doses
of NR-triflate, the control arm with sodium triflate.
Storage lesion was monitored for 23 days. Platelet
metabolic and functional parameters were tested.
Clearance of human platelets was measured in a mouse
model of transfusion.
RESULTS: Total intracellular NAD levels in platelets
decreased two-fold from 4.8  0.5 fmol (mean  SD,
n = 6) to 2.1  1.8 fmol per 103 control cells, but
increased almost 10-fold to 41.5  4.1 fmol per 103 NR
treated platelets. This high intracellular NAD level had no
significant impact on platelet count, mean platelet
volume, swirling, nor on lactate and glucose levels.
Platelet aggregation and integrin αIIbβ3 activation
declined steadily and comparably in both conditions.
GPIbα levels were slightly lower in NR-treated platelets
compared to control, but this was not caused by reduced
receptor shedding because glycocalicin increased
similarly. Apoptotic markers cytochrome c, Bcl-xL,
cleaved caspase-3, and Bak were not different
throughout storage for both conditions. Platelet survival
in a mouse model of transfusion was not different
between NR-treated and control platelets.
CONCLUSION: Platelets carry the cellular machinery to
metabolize NR into NAD at rates comparable to other
eukaryotic cells. Unlike those cells, platelet life-span
cannot be prolonged using this strategy.
P
latelet transfusion is essential for the acutely
bleeding patient and for the patient at risk for
bleeding during periods of thrombocytopenia.
Platelet concentrate (PC) stock management is a
tremendous challenge because of the limited shelf life. This
is caused by a quick decline in platelet quality and by the
risk of bacterial bloom during storage at 22°C. The latter
may be prevented by pathogen inactivation techniques,1 but
this comes at a cost of platelet damage2–4 and increased
complexity during component processing.5,6
One classical diagnostic determinant for platelet quality
is pH. The acid–base balance is used for research purposes
but very often also for routine quality control checks of PC
stock. The Council of Europe, AABB, and FDA guidelines
therefore define a lower quality limit to pH ≥ 6.4 and pH
≥ 6.2, respectively.7 Platelet metabolism consequently is at
the center of quality assessment in blood institutions. The
biochemical explanation behind this parameter is that plate-
lets produce lactic acid relatively constant in time by anaer-
obic respiration. Platelet aging will therefore inevitably lead
to increased acidity of the milieu allowing to monitor senes-
cence relatively easy. Lactic acid production rate has been
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one of the few parameters that correlates reasonably well
with transfusion yield.8 Of note, oxidative phosphorylation
in mitochondria still significantly contributes to the plate-
let’s ATP pool by fueling alternative energy sources like L-
glutamine and fatty acids.9 Hence, the electron transport
chain is a functional metabolic system in platelets. Its opti-
mal function depends on many variables which is reflected
in complex metabolic shifts during storage.10 Pivotal to res-
piration are the nicotinamide adenine dinucleotides (NAD)
NAD+ and NADH. This redox couple functions to shuttle
electrons back and forth in a variety of cellular reactions
and its ratio NAD+/NADH controls the activity of several
enzymes.11
However, recent discoveries have also put NAD at the
center of a search for treating senescence-related diseases
because senescing cells, tissues, and organisms gradually
loose NAD.12,13 These changes in cellular NAD levels occur
when pathways that regulate NAD biosynthesis and con-
sumption are modulated. Oxidative damage for instance
can lead to increased NAD consumption, by enzymes of the
poly ADP-ribose polymerase (PARP), cyclic ADP-ribose
synthase (CD38 and CD157), and sirtuin families.14 Omics
studies have detected members of these families in
platelets.15–17 In the absence of NAD synthesis, increased
consumption will inevitably lead to NAD decline and
decreased cellular function.18 As a consequence, dietary
delivery of NAD by supplementation of niacin precursors
like nicotinamide mononucleotide (NMN) and nicotinamide
riboside (NR) has been shown to increase viability of cells,
tissues, and entire organisms.19,20
Because platelet quality declines fast when stored
ex vivo and because this is often attributed to senescence-
related metabolic dysregulation, we investigated if platelets
can raise NAD content when supplemented by NR and
whether this influences platelet quality and transfusion yield
during long-term storage in blood banking conditions.
MATERIALS AND METHODS
Study design
Nicotinamide riboside was synthesized at NovAliX-Pharma
as a trifluoromethanesulfonate salt21 (triflate). As a vehicle
control, an equimolar solution of sodium triflate (Sigma-
Aldrich) was used. PCs were prepared by pooling of buffy
coats following voluntary whole blood donation as
described.22 On Day 1 post phlebotomy, 2 PCs were pooled
and split to prepare paired samples to be treated either by
NR or vehicle control solution (Fig. S1, available as
supporting information in the online version of this paper).
Addition of NR or vehicle control solution was performed
on Days 1, 5, 9, 12, 16, and 19 post phlebotomy by sterile
connection to 500 mM of compound in distilled water. Vol-
umes added ranged between 0.2 mL and 0.5 mL. Conse-
quently, 154 nmol of NR or sodium triflate was added per
109 platelets per day. Throughout the study, both PCs were
stored in standard blood banking conditions on a flatbed
agitator (PF48i, Helmer Scientific) at room temperature.
Samples for experiments were taken aseptically on Days
1, 2, 5, 7, 9, 12, 13, 16, 19, and 23 ranging between 1 and
8 mL depending on the experiments to be performed. On
Day 1, a sample was taken from the pool, prior to splitting
and representing “baseline” values (Fig. S1, available as
supporting information in the online version of this paper).
At the end of the study (Day 23) PCs were checked for ste-
rility by inoculation of a 1.5 mL sample in Luria Bertani agar
(Sigma-Aldrich) at 37°C for 24 hours followed by visual
inspection. Even though less relevant for clinical applica-
tion, follow-up beyond 7 days was chosen to study platelet
longevity in the presence or absence of NR.
PC preparation
PCs were prepared by the buffy coat method from voluntary
whole blood donations as described before.22 In brief, six
ABO blood group matched buffy coats were manually
pooled and supplemented with 280 mL SSP+ additive solu-
tion (Macopharma). Next, the bag was centrifuged at 542 g
for 450 seconds at 22°C to separate red and white cells from
platelets. The buoyant platelet suspension was taken off by
automated separation (Macopress Smart, Macopharma)
while passing over a leukocyte reduction filter. Next, the
PCs were stored at 22°C  2°C in a temperature controlled
environment with continuous agitation.
Swirling, platelet counts, mean platelet volume, and
metabolic parameters
PCs were assessed visually for swirling, yielding an integral score
between 0 and 3. A low swirling score indicated an aberrant
platelet morphology and deteriorating quality. PC with a swirling
score ≥ 2 are considered suitable for transfusion. Platelet counts
and mean platelet volume (MPV, fL) were measured using an
automated hematology analyzer (pocH-100i, Sysmex). Metabo-
lites of respiration were measured in a point-of-care blood gas
analyzer (RAPIDPoint 500, Siemens).
Platelet aggregation
Platelet aggregation was examined with light transmission
aggregometry at 37°C (Chrono-Log, Helena Laboratories).23
Platelet aggregation was with 25 μg/mL fibrillar collagen
(Stago) or a combination of 10 μM Thrombin Receptor Activat-
ing Peptide 6 (TRAP6, Sigma-Aldrich), 20 μM 2-(Methylthio)
adenosine 5-diphosphate trisodium salt hydrate (MeSADP,
Santa Cruz Biotechnology) and 5 μM epinephrine (Sigma-
Aldrich). For aggregation studies, platelets were diluted to
250,000 cells/μL in autologous platelet-free supernatant. Maxi-
mal aggregation (amplitude [%]) is reported in this study.
166 TRANSFUSION Volume 60, January 2020
DELABIE ET AL.
Western blotting
For western blotting of intracellular proteins, platelets were
washed twice in Tyrode’s buffer (5 mM 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid (HEPES) pH 7.4 with
136.5 mM NaCl, 2.7 mM KCl, 11.9 mM NaHCO3, 0.4 mM
NaH2PO4, 1 mM MgCl2 and 0.1% (wt/vol) D-glucose)
supplemented with 1 μg/mL tirofiban (Sigma-Aldrich) to
prevent aggregation. Glycocalicin was determined in
platelet-free supernatant prepared by centrifugation at 1000 g
for 12 minutes in presence of 0.5 mg/mL prostaglandin E1
(PGE1) and 0.2 μm filtration. For preparation of whole cell
lysate, platelets were pelleted and resuspended in ice cold lysis
buffer (50 mM tris(hydroxymethyl)aminomethane (tris)–HCl
pH 8.0, 150 mM NaCl, 1.0% (vol/vol) octylphenoxy
poly(ethyleneoxy)ethanol (IGEPAL CA-630), 0.5% (wt/vol)
sodium deoxycholate, 0.1% (wt/vol) sodium dodecyl sulphate
(SDS), 2 mM ethylenediaminetetraacetic acid (EDTA) and
10 mM sodium orthovanadate) with additional 2% (vol/vol)
protease and phosphatase inhibitor (Thermo Fisher Scientific).
The Mem-PER Membrane Extraction system (Thermo
Fisher Scientific) was used for the preparation of cytosolic
and membrane fractions. Samples were diluted in Laemmli
buffer (60 mM Tris, 10% [vol/vol] glycerol, 2% [wt/vol] SDS,
41.7 mM dithiothreitol [DTT] and 0.01% [wt/vol] brom-
ophenol blue) for SDS polyacrylamide gel electrophoresis
(PAGE) and western blotting. The samples were stored at
−20°C until used for analysis.
Total protein in samples was determined with a colori-
metric bicinchoninic acid assay (Thermo Fisher Scientific).
All samples were incubated at 100°C for 5 minutes. Total
protein levels of 46 μg for cleaved caspase-3, 1.4 μg for Bcl-
xL, 25 μg for Bak, and 20 μg for cytochrome c were loaded
onto precast polyacrylamide gels (Bio-Rad). Proteins were
transferred on polyvinylidene fluoride (PVDF) membranes
using a semi-dry turbo transfer system (Bio-Rad). All anti-
bodies were purchased from Cell Signaling Technology or
United States Biological. Primary and secondary antibodies
were prepared in Tris buffered saline (TBS pH 7.4, 25 mM
Tris with 150 mM NaCl and 2 mM KCl) with 5% (wt/vol)
skimmed milk. Loading control proteins were detected on
the same membranes following stripping by incubation for
30 minutes at 60°C in western reprobe buffer (50 mM Tris
pH 7.0, 2.0% [wt/vol] SDS and 100 mM β-mercaptoethanol).
Bound antibody was detected with enhanced chemilumi-
nescence and an imaging system (ChemiDoc MP, Bio-Rad)
equipped with a CCD camera and analysis software (Image
Lab v4.0.1, Bio-Rad) for densitometry.
Total nicotinamide adenine dinucleotide levels
Extraction and detection of total nicotinamide adenine
dinucleotide (NAD) levels was performed using an
NAD/NADH colorimetric assay kit (Abcam) according to the
manual with minor adaptations. In brief, platelets were
washed in ice cold 10 mM HEPES buffer with 0.9% (wt/vol)
NaCl (HBS), pH 7.4. Platelets were then resuspended in
extraction buffer and lysed by multiple freeze-thawing
cycles in liquid nitrogen and a 37°C water bath. Total NAD
was determined by interpolating the data obtained from col-
orimetric measurements (Infinite F200 Pro, Tecan Group
Ltd.) in a 96-well microplate containing the NAD standard
in the kit.
Thrombin generation assay
To study platelet’s contribution in coagulation, a thrombin
generation assay (Technoclone GmbH) was performed as
described.24 In brief, platelets were centrifuged, resuspended,
and diluted to 250,000 per μL, 100,000 per μL, 50,000 per μL,
or 10,000 per μL (final concentrations after addition of sub-
strate) in a fixed volume of heterologous normal human
plasma pooled (n = 38 healthy donors). The assay was per-
formed with varying platelet concentrations to demonstrate
platelet dose dependence.25 In a fixed volume 1:10,000
(vol/vol) purified recombinant human tissue factor (TF) (Dade
Innovin from Siemens Healthcare GmbH), 4.0 μM corn trypsin
inhibitor (CTI, enzyme research laboratories), and 0.5 μM
fluorogenic substrate (Z-G-G-RAMC, Technoclone GmbH)
was mixed in a 96-well microplate and immediately analyzed
in a microplate reader equipped with filters for excitation and
emission wavelengths of 380 nm and 485 nm, respectively.
The fluorescent signal was recorded in function of time for a
total of 120 minutes at 37°C. The raw signal was converted to
thrombin concentrations based on a calibration kit and a
script in Excel (Microsoft) provided by the manufacturer.26
Murine model for platelet clearance
A previously described murine model for platelet transfu-
sion and platelet clearance was used.27 Platelet samples
were supplemented with 0.5 mg/mL PGE1 to prevent acti-
vation and centrifuged next at 1000 g for 12 minutes. The
platelet pellet was resuspended to a final concentration of
4 × 109 platelets per mL in its autologous supernatant. A
bolus of 100 μL (4 × 108 platelets) was injected into immu-
nodeficient NOD SCID IL2R common gamma chain knock-
out mice (NSG) via the tail vein. Murine blood was collected
at 1 minute and then 1, 2, 5, and 24 hours post transfusion
through retro-orbital bleeding. Blood was mixed 1:16 in
anticoagulant citrate dextrose solution, solution A (ACD-A,
38.0 mM citric acid, 123.8 mM D-glucose and 74.8 mM tri-
sodium citrate dissolved in distilled water, pH 5). Anti-
coagulated blood was fixed (Beckman Coulter) and samples
were stored on a rotator at 4°C until read out by flow cyto-
metry. All animal experiments were approved by the local
ethical committee (107/2017, KULeuven, Leuven, Belgium).
Flow cytometry
Expression of P-selectin (phycoerythrin-anti-CD62P, Life
Technologies), phosphatidylserine (peridinin-chlorophyll-
Cy5.5 Annexin V, BD Biosciences), activated integrin αIIbβ3
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(fluorescein-labeled PAC1, BD Biosciences) and GPIbα
(fluorescein-labeled anti-CD42b, Life Technologies) was
analyzed with an acoustic focusing flow cytometer (Attune,
Life Technologies). In fixed murine blood, human platelets
(allophycocyanin-labeled mouse anti-human CD41, BD Bio-
sciences) and murine platelets (fluorescein-labeled rat anti-
mouse CD42b, BD Biosciences) were measured separately.
Data are expressed relative to the number of human plate-
lets per 10,000 murine platelets in the 1 minute post trans-
fusion sample. Samples were incubated with labeled
antibodies for 10 minutes in HBS with 1 mM MgSO4 and
5 mM KCl at room temperature. Samples were diluted
20-fold in the same buffer, immediately before readout. For
phosphatidylserine measurements with annexin V buffers
were supplemented with 2 mM CaCl2. The fraction (%) of
activated platelets is defined as the PAC1 positive platelet
population either in resting conditions or after activation
with TRAP6 at 2.5, 5.0, and 25 μM.
Threshold gates were set including 0.5% of 10,000 events
incubated with corresponding isotype antibody controls. For
phosphatidylserine controls, a sample containing labeled
annexin V was prepared without CaCl2. Percentage positive
events or median fluorescent intensities (MFI) were determined
for 10,000 events staining positive for CD61 (allophycocyanin-
labeled anti-CD61, Life Technologies). The number of micro-
particles was determined using calibration beads (BioCytex)
and the accompanying gating strategy provided by the manu-
facturer. Microparticles were determined as GPIbα positive
events with sizes smaller than 0.9 μm (detection limit of flow
cytometer is 0.5 μm). The result is expressed as the fraction of
microparticles per 10,000 all-size events positive for GPIbα.
Statistical analysis
All statistical analyses were performed using Prism Ver-
sion 7.04 (GraphPad Software Inc.). A repeated measures
two-way ANOVA for test (NR) versus control (triflate) as a
function of storage time was used. A Sidak correction for
multiple comparison was included. Significance was
assumed when p < 0.05.
RESULTS
NAD content in platelets
Total NAD levels increased rapidly and significantly during
NR treatment compared to control. At the end of the study
(day 23) an average NAD content of 41.5  4.1 fmol was
found per 103 platelets in NR treated platelets. This repre-
sented a nine fold increase from the initial NAD content of
4.8  0.5 fmol per 103 platelets (Fig. 1). In control cells, reg-
ular senescence led to a two-fold decrease in NAD levels of
2.1  1.8 fmol per 103 platelets. Total NAD levels were sig-
nificantly higher (p ≤ 0.0001) for NR treated platelets com-
pared to control platelets from Day 5 on.
Influence of NR on PC quality
Platelet count decreased similarly in NR and control condi-
tions (Fig. 2A). MPV slowly increased (Fig. 2B) in both con-
ditions. Swirling remained intact until Day 12 when a
decrease was detected which was not different between
conditions (Fig. 2C). Platelet anaerobic metabolism was lin-
ear until Day 12 (Fig. 2D) when glucose levels (Fig. 2E) fell
below detection limit (1.1 mM) and pH started to slightly
rise (Fig. 2F). A small but significant difference in pH was
found between NR treated and vehicle control treated PC
(p ≤ 0.0001) from Day 12 on. There were no significant dif-
ferences between NR and vehicle treated platelets for the
parameters shown in Fig. 2A-E.
Influence of NR on platelet activation
Platelet aggregation significantly decreased in aging platelets
irrespective of NR supplementation (Fig. 3). This was the
same for both activation with collagen (Fig. 3A) or with a
combination of TRAP6, MeSADP, and epinephrine (Fig. 3B),
even though in the latter case NR supplemented platelets
retained aggregation slightly better over storage time. Dur-
ing aging, NR and control PC contained increasing numbers
of platelets with spontaneously activated integrin αIIbβ3
receptors (Fig. 4A). NR treated platelets were slightly less
activated than control platelets and this was significant from
Day 19 on (p ≤ 0.01). Integrin αIIbβ3 activation in response
to TRAP6 decreased in both conditions during storage
(Fig. 4B).
Regardless of platelet storage, thrombin generation was
always dependent on platelet concentration (Fig. S2, avail-
able as supporting information in the online version of this
Fig. 1. Intracellular total NAD levels in platelet lysates. Total
NAD was measured in platelet lysates during storage of
PC. Dotted lines indicate when addition of NR or vehicle solution
was performed. Samples were collected on Days 1, 5, 7, 12,
19, and 23 from PC supplemented with NR () or control (●).
Data are shown as mean with SD (n = 6), ****p < 0.0001.
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Fig. 2. Blood banking parameters. (A) Platelet count and (B) MPV were measured by a hematology analyzer. (C) Swirling was scored
blinded by trained blood banking staff. The energy metabolites (D) lactate, (E) glucose, and (F) pH at 21°C were measured with a point-
of-care blood gas analyzer. The detection limit for glucose is 1.1 mM. Data were collected on Days 1, 5, 7, 12, 19, and 23 from PC
supplemented with NR () or control (●). Data are shown as mean with SD (n = 6), ****p < 0.0001.
Fig. 3. Platelet aggregation. Platelet aggregation was induced with either (A) collagen or (B) a combination of TRAP, MeSADP and
epinephrine and measured using light transmission aggregometry at 37°C. Data were collected on days 1, 5, 7, 12, 19, and 23 from PC
supplemented with NR () or control (●). Data are shown as mean with SD (n = 6), *p < 0.05.
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paper). However, peak thrombin values increased as a func-
tion of storage. No significant differences were found
between NR treated and control platelets.
Storage lesion
Phosphatidylserine expression remained stable until Day
7, but exponentially increased thereafter (Fig. S3A, available
as supporting information in the online version of this
paper) independent of NR supplementation. GPIbα expres-
sion decreased linearly as a function of storage in both con-
ditions but at a slightly faster rate in NR treated platelets
compared to control (Fig. S3B, available as supporting infor-
mation in the online version of this paper). Correspondingly,
glycocalicin levels increased 20-fold during storage but, unlike
the corresponding data in flow cytometry this difference was
not significant between conditions (Fig. 5). Platelet degranula-
tion determined by P-selectin exposure increased comparably
in both conditions (Fig. S3C, available as supporting informa-
tion in the online version of this paper). The number of micro-
particles increased just slightly during storage and was not
different between conditions (Fig. S3D, available as supporting
information in the online version of this paper).
Apoptosis
Mitochondrial cytochrome c release into the cytoplasm dis-
played an increasing trend which was similar for NR
Fig. 4. Activation of platelet integrin αIIbβ3. Activated integrin αIIbβ3 was detected using PAC1 binding in flow cytometry on (A) resting
platelets or on (B) platelets activated with 25 μM TRAP6. Data were collected on days 1, 5, 7, 12, 19, and 23 from PC supplemented with
NR () or control (●). Data are shown as mean with SD (n = 6), *p < 0.05, **p < 0.01, and ****p < 0.0001.
Fig. 5. Glycocalicin levels in platelet concentrate (PC) supernatant. GPIbα shedding was determined by detection of glycocalicin using
SDS-PAGE and quantitative western blotting. (A) Band intensities are expressed relative to those on Day 1. (B) A representative western
blot of glycocalicin in PC supernatant. Data were collected on Days 1, 5, 7, 12, 19, and 23 from PC supplemented with NR (open bars) or
control (closed bars). Data are shown as mean with SD (n = 6).
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supplemented and control platelets (Fig. 6A). This was not sta-
tistically significant. The anti-apoptotic Bcl 2 family protein
Bcl-xL prevents cytochrome c release and its levels corre-
spondingly declined in whole platelet lysates (Fig. 6B). Cleaved
caspase-3 was detected from Day 19 on and increased 4 days
later (Fig. 6C) indicating effector caspase activation in these
later stages of storage. No changes in the pro-apoptotic
membrane residing Bak protein were found (Fig. 6D). For all
parameters tested, the presence of NR made no difference.
Transfusion in mice
As expected, circa half of human platelets were quickly
cleared from murine circulation during the first hour after
Fig. 6. Intrinsic apoptosis. Key proteins of the intrinsic apoptosis pathway were detected in SDS-PAGE western blotting. (A) Cytochrome
c, (B) Bcl-xL in whole cell lysate, (C) cleaved caspase-3 (Cl-Cas-3) in whole cell lysate and (D) Cytosolic Bak. Data for cleaved caspase-3
were below the detection limit on Days 1, 5, and 12 (C). Western blotting inserts to the right of each graph are representative for the
data. Data were collected on Days 1, 5, 7, 12, 19, and 23 from PC supplemented with NR (open bars) or control (closed bars) and are
shown as fold increase relative to that on Day 1 except for panel C where absolute intensities are given. Data are shown as mean with SD
(n = 6), *p < 0.05, ***p < 0.001.
Fig. 7. Human platelet transfusion in NSG mice. Mice were transfused with aging platelets treated with NR () or not (●). On Day 2 (A),
Day 7 (B), and Day 13 (C) of storage, 4 × 108 platelets were delivered via the tail vein (n = 3 biological repeats). Blood was taken at
1 minute, 1 hour, 2 hours, 5 hours, and 24 hours after transfusion. Data are expressed relative to the number of human platelets per
10,000 murine platelets in the 1 minute post transfusion sample.
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transfusion (not shown) in both NR and control conditions
and this was similar for all time points tested during storage.
This rapid decrease was followed by slower platelet clear-
ance until less than 20% of initial human platelets were
detected 24 hours after transfusion (Fig. 7).
DISCUSSION
Platelets for transfusion are stored as a hyperconcentrated sus-
pension contained in plastic bags. The suspension is continu-
ously agitated at controlled temperatures near 22°C. In these
storage conditions, platelet anaerobic metabolism eventually
leads to acidosis and subsequent storage lesion.28,29 Platelets
are metabolically active cells and respond quickly to environ-
mental disturbance by cell activation which is regulated by
Ca2+ fluxes. This way, platelets generate ATP at six times the
rate of muscle cells and 13 times the rate of red cells.30 Long
term storage of platelets ex vivo therefore is a challenge of
controlling metabolic (stress) rate.
As in other cells, platelets produce reducing equivalents
in the tricarboxylic acid cycle (alternative names: Kreb’s or
citric acid cycle) by reduction of NAD+ to NADH. In most
cells, NAD availability therefore is an important determinant
of mitochondrial respiration and cell survival. Yet, NAD is
not only consumed during mitochondrial respiration. The
NAD molecule acts as a crucial coenzyme in other biochem-
ical pathways where it is catabolized, hence not recycled.
Sirtuins and PARPs constitute the bulk of such NAD scaven-
gers and these enzymes have been detected in platelets at
the RNA level.15–17 This way, NAD content declines during
aging and has been found to be at the nexus of senescence
signaling.14 Consequently, caloric restriction and/or dietary
supplementation of NAD precursors like NR can retain or
restore NAD levels and attenuate some molecular effects of
aging.31
Our study shows that when assuming a mean platelet
volume of 9 fL, the intracellular NAD content in resting
healthy donor platelets is 533 μM on average. We found no
similar studies that have measured NAD levels in platelets,
so could not compare with existing studies. An older study
in human red blood cells found just 42 nmol per mL of
“packed red blood cells.” An estimation of the total cell vol-
ume in such conditions assuming 60% hematocrit returns
an intracellular NAD concentration of 70 μM which is seven
times less than platelets. However, it is suggested that in
general, mammalian cells bear intracellular NAD concentra-
tions >200 μM.32 For instance, measurements in human
brain tissue returned an intracellular NAD concentration of
370 μM, in vivo.33
The past decades have provided evidence that raising
NAD levels by supplementation of niacin precursors to cells,
tissues, or entire organisms can rejuvenate and even extend
life-span.34 Platelets are no different and respond to NR
supplementation by increasing intracellular NAD levels. In
our study, NAD content in platelets increased at an average
rate of 1.5 fmol per 1000 cells per day, resulting in an almost
10-fold increase at the end of the 23-day study yielding mil-
limolar concentrations of intracellular NAD. The rate of
NAD synthesis is strikingly similar to other mammalian cells
supplemented in vitro with similar concentrations of NR.35
For instance, when HEK293 cells were supplemented with a
similar concentration of NR (~600 μM), its NAD content
almost doubled in the course of 2 days of tissue culture.
This demonstrates that platelets carry the molecular
machinery of salvage pathway NAD synthesis and readily
respond to precursor supplementation by increasing intra-
cellular NAD levels. At the same time, control senescent
platelets gradually lost NAD over the course of the study
indicating that also platelets suffer from decreasing NAD
levels while aging (ex vivo).
This prompted further study into platelet storage lesion
because the response of platelets to high intracellular NAD
levels was unknown. Despite this however, NR treated
platelets were no different from control untreated platelets.
This also implies that supraphysiologic levels of NAD were
not detrimental to platelets, at least for those parameters
tested in this study. Three major platelet assay groups can
be distinguished in our study: one was examining direct
platelet storage lesion parameters typical to blood banking,
the second dealt with activation and apoptotic markers and
the third with transfusion itself in a preclinical animal
model.
The typical blood banking quality control parameters
were chosen to study platelet metabolism output data dur-
ing long term storage in the presence or absence of
NR. These data typically inform transfusion specialists on
the expected success of a platelet transfusion. It often works
in one way, i.e., when MPV is high, pH is low and swirling
is absent a poor transfusion efficiency is to be expected. The
other way around is not necessary valid, i.e., when MPV, pH
and swirling is normal, then transfusion not necessarily
yields a long term donor platelet survival in the patient’s cir-
culation.36 So despite the absence of any differences
between NR and control it could not be excluded that NR
platelets would be better than control for other output
parameters like hemostasis or aggregation.
However, this was not the case. PCs containing NR
were not particularly more responsive to agonists in integrin
activation or aggregation. This implies that high NAD con-
centrations do not boost the platelet’s activation response
by increasing the aggregation amplitude. It also means that
high NAD levels do not cause an increase in the sustainabil-
ity of the activation response over the course of storage.
Using our supplementation strategy based on literature in
different fields, NR caused supraphysiologic intracellular
NAD levels. Whether these abnormally high NAD levels
influence the platelet such that putative beneficial effects of
NR supplementation are counterbalanced, needs further
investigation. If so, a careful titration of NR to maintain
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baseline NAD levels instead of supraphysiologic levels
would be a better strategy.
Finally, because platelet clearance from circulation is
hard to predict from in vitro data8 we chose to infuse these
platelets in immunodeficient mice. Clearance of human
platelets in these mice is inherently variable,27 so conclusive
data were not obtained. However, obvious differences
between NR and control were not found, suggesting that
any effect is small or negligible. In addition, the in vivo find-
ings correlate with our in vitro data. The small difference in
GPIbα expression levels found in flow cytometry suggested
that circulation time might be different, but this was not the
case. Our glycocalicin measurements indeed suggest that
GPIbα expression differences were not related to shedding.
In conclusion, despite promising results on NR supple-
mentation and longevity in single cells, tissues and whole
animals in other studies,34 no measurable attenuation of
storage lesion can be found in platelets treated with NR
ex vivo. One explanation may be the absence of a strong
gene-driven survival response. Platelets are anucleate and
some of the sirtuins that regulate senescence in nucleated
cells are located inside the nuclear compartment where NR
supplementation may lead to gene regulated responses. If
these constitute the bulk of the senotherapeutic effect, then
it is sensible that platelets do not respond to NR by increas-
ing life-span. Of note, a recent randomized, double-blind,
placebo-controlled, crossover trial has provided evidence
that NAD metabolism is stimulated in healthy middle-aged
and older adults taking NR as a dietary supplement.37 The
authors assessed cardiovascular outcomes of which none
was significantly different compared to placebo, but none-
theless some interesting trends were reported. It therefore
remains to be independently proven that NR supplementa-
tion to single cell cultures, entire tissues or even humans
extends life-span or ameliorates quality of life.
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